logo
Miliband eyes refinery support after Lindsey collapse

Miliband eyes refinery support after Lindsey collapse

Yahoo15 hours ago

Ministers are exploring ways to hand state support to Britain's remaining oil refineries as they scramble to deal with the fallout from the collapse of the Prax Lindsey site in Lincolnshire which has cast a shadow over hundreds of jobs.
Sky News understands that Ed Miliband, the energy security secretary, wants to devise a mechanism for refineries to become eligible for the Energy-Intensive Industries Compensation Scheme - from which they are currently excluded.
Energy costs were at the heart of the government's industrial strategy launched last week.
Money latest:
Such a move would hand a welcome financial boost to the sector by assisting them with energy costs amid a slew of challenges which culminated in the appointment of compulsory liquidators over the Prax Lindsey refinery on Monday.
The site's insolvency - revealed by Sky News - has drawn strong criticism from the government, with energy minister Michael Shanks calling the development "deeply concerning".
"There have been longstanding issues with this company and workers have been badly let down," he said.
"The secretary of state is today writing to the Insolvency Service to demand an immediate investigation into the conduct of the directors, and the circumstances surrounding this insolvency.
"The government will ensure supplies are maintained, protect our energy security, and do everything we can to support workers and the local community, including engaging with trade unions and industry bodies.
"The company has left the government with very little time to act."
Prax Group is owned by Sanjeev Kumar Soosaipillai, who also acts as its chairman and chief executive and is the sole director of the refining subsidiary.
The crisis at the Lindsey refinery, which is located on a 500-acre site five miles from the Humber Estuary, echoes that at Britain's dwindling number of oil refineries.
According to the company, the site has an annual production capacity of 5.4 million tonnes, processing more than 20 different types of crude including petrol, diesel, bitumen, fuel oil and aviation fuels.
The refinery, which was bought from France's Total in 2020, is understood to have become a growing drain on cash across the wider Prax Group, with which it has cross-guarantees.
About 180 people work at State Oil Ltd, Prax Group's parent entity, while roughly 440 more are employed at the Prax Lindsey Refinery.
Read more from Sky News:
The rest of the group, which includes oilfield assets in the Shetland Islands and hundreds of UK petrol stations, employs hundreds more people.
The other assets are not in administration themselves but are expected to be sold as part of the reorganisation of the group.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The World's Greatest McLaren Collection Is Up for Sale
The World's Greatest McLaren Collection Is Up for Sale

Motor 1

timean hour ago

  • Motor 1

The World's Greatest McLaren Collection Is Up for Sale

McLaren would not be what it is today without Mansour Ojjeh. The businessman took an ownership stake in McLaren in 1984, and together with Ron Dennis, helped turn it into the top-flight Formula 1 team and supercar builder it is today. Ojjeh passed in 2021, and now, his car collection is coming up for sale. It might be the greatest collection of McLaren road cars ever assembled. As seller Tom Hartley Jnr. states , Ojjeh was pivotal in helping fund the McLaren F1, and the car is the centerpiece of the collection. It's the last of 106 McLaren F1s built in total, and it's finished in a shade of orange called Yquem, which McLaren later renamed Mansour Orange. It's a color McLaren kept exclusive to him. The rest of the collection consists of last-built examples of many special modern McLaren road cars, including the Sabre, Speedtail, Senna, Elva, P1, and what appears to be one of every LM and LT model. Photo by: Tom Hartley Jnr Not all are Mansour Orange, with the Senna in a bare-carbon, yellow, and green livery, and the 675LT Spider in bare carbon with orange accents. Most of the cars were never driven, either, with only the F1 having 1,810 km (1,125 miles) on its odometer, and the P1 GTR used at a handful of McLaren track days. Ojjeh was actually a Ferrari collector at first, but he sold his collection when he helped found McLaren Automotive. It's hard to imagine a better collection of McLaren road cars, certainly outside of the company's collection of F1s. And it's easy to bet that there will be tons of people lining up for the chance to buy an F1 from the man who helped make it a reality. More on McLaren Longtime Ferrari Boss Might Be Working for McLaren McLaren Is Milking Its Le Mans History Again. But We're Here for It Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . Gallery: Mansour Ojjeh McLaren Collection 30 Source: Tom Hartley Jnr. Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )

1 sneaky UK growth stock to consider in July
1 sneaky UK growth stock to consider in July

Yahoo

time2 hours ago

  • Yahoo

1 sneaky UK growth stock to consider in July

Growth stocks come in all shares and sizes. You've obviously got the likes of Nvidia (NVDA), with its eye-popping growth rates, or Rolls-Royce (RR.L), which has positively transformed its profit margins. Then there's WH Smith (SMWH.L), which is a UK stock that may raise a few eyebrows when associated with growth. After all, many people might still associate the company with its high street stores, the first of which opened in London in 1792. But, sadly, there isn't much growth happening today on British high streets. E-commerce and high taxes are doing the irreversible damage there. In March, WH Smith announced it would sell its 480 high street shops to Modella Capital for £52m in gross cash proceeds. However, it announced today (30 June) that it now expects up to £40m. This will be made up of £10m expected in FY25, up to £20m in FY26, and £10m of deferred tax assets to be realised later. In other words, it's accepting £12m less to get the deal done, after a recent period of softer trading forced Modella to renegotiate the original deal. In response, the WH Smith share price dropped as much as 5% today, before clawing back some losses. It's now trading 2.5% lower at 1,100p. Here's why I think this FTSE 250 (^FTMC) stock is worth considering at this price. This transaction now positions WH Smith, which is keeping its brand, as a travel retailer. As the company puts it, 'This creates a pure play global travel retailer which is well positioned to capture the substantial global growth opportunities in its key markets and drive enhanced shareholder value'. Unlike the falling footfall and unappealing economics of the high street, global travel is a structural growth market. Over the next couple of decades, global airport passenger numbers are expected to double, and that will need a lot of investment in airport infrastructure. WH Smith already operates around 1,300 stores in airports, train stations, and hospitals across 32 countries worldwide. While growth at UK travel hubs is likely to remain limited due to opposition on environmental grounds, the Asia-Pacific and Middle East regions are expected to lead the charge. I like this pivot, as the challenges WH Smith faced on the high street aren't nearly as strong in travel retail. At airports and train stations, there's a captive audience with time to kill and far fewer alternatives. No one's browsing Amazon (AMZN) for a bottle of water or the neck pillow they forgot to pack! Back in FY19, WH Smith reported revenue of £1.4bn and a £106m net profit. Then the pandemic hit the business like a sledgehammer, resulting in losses and higher debt. For FY26, which starts in September, revenue is expected to be £1.74bn, with a net profit of £114m. Yet the share price is still more than 50% lower than before Covid, despite the firm bouncing back strongly. Indeed, it's gone nowhere for five years now! Looking ahead, the company expects headline net debt to increase to £425m by August, above previous expectations for £400m. So the balance sheet is a risk worth watching. However, the stock looks cheap enough to consider, in my opinion. It's trading for less than 13 times forward earnings, while offering a 3% dividend yield. The post 1 sneaky UK growth stock to consider in July appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Ben McPoland has positions in Nvidia and Rolls-Royce Plc. The Motley Fool UK has recommended Amazon, Nvidia, Rolls-Royce Plc, and WH Smith. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Iksuda Therapeutics Receives FDA IND Clearance for IKS014
Iksuda Therapeutics Receives FDA IND Clearance for IKS014

Associated Press

time2 hours ago

  • Associated Press

Iksuda Therapeutics Receives FDA IND Clearance for IKS014

NEWCASTLE, England--(BUSINESS WIRE)--Jun 30, 2025-- Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IKS014, a human epidermal growth factor receptor 2 (HER2) ADC targeting patients with advanced HER2+ solid tumours, enabling the expansion of ongoing clinical trials. IKS014 is currently being investigated in an open-label phase 1 dose-escalation study ( ) designed to evaluate the safety and tolerability of increasing dose levels of IKS014 and establish a recommended phase 2 dose. Preliminary data from this study has demonstrated promising clinical activity across multiple tumour types, including breast, ovarian, gallbladder, and oesophageal cancers, and including patients who have relapsed after prior treatment with Enhertu. Gaining access to U.S. centres for the dose expansion stage of this phase 1 trial will enable efficient confirmation of the role of IKS014 in this important patient sub-set. Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said: 'The FDA clearance of our IND application for IKS014 represents a significant milestone in our mission to address the critical unmet needs of patients with HER2-positive cancers, particularly those who have exhausted current standard-of-care options. Early clinical data has been extremely encouraging, and we are excited to expand our program to reach more patients. 'The early efficacy signals that have been observed, particularly in patients that have relapsed after receiving prior treatments of Kadcyla and Enhertu, suggest IKS014 could potentially offer a new treatment option for patients who currently have limited alternatives. We look forward to working with our clinical partners to further evaluate the potential of IKS014.' The first stage of this phase 1 trial, to determine the recommended phase 2 dose for dose expansion, is nearing completion. The expansion phase will assess several patient cohorts including those with HER2-positive breast cancer who are refractory to or cannot tolerate Enhertu, patients with HER2-low breast cancer and patients with HER2-positive positive gastric cancer. The IND clearance will allow Iksuda to access patients across sites in the United States, alongside sites in Australia, New Zealand, and Singapore. The phase 1 trial is expected to complete in 2H 2026. About IKS014 IKS014 is a potential best-in-class antibody drug conjugate, benefiting from tumour selective activation and release of the cytotoxic agent monomethyl auristatin F (MMAF). In preclinical trials, it displayed impressive activity in high- and low-HER2 expressing tumours with a favourable Therapeutic Index vs other HER2-directed drugs. Iksuda gained exclusive world-wide rights (excluding Greater China and South Korea) to IKS014 from LigaChem Biosciences ( ). About Iksuda Therapeutics: Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda's pipeline of ADCs is centred on a portfolio of prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink ® platform. The Company's design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer. View source version on CONTACT: For further information please contact: Iksuda Therapeutics Dave Simpson, Chief Executive Officer Tel: +44 (0) 191 6031680 [email protected] Consulting (Financial Media and IR) Simon Conway / Rob Winder / Amy Byrne Tel: +44 (0) 020 3727 1000 [email protected] KEYWORD: NORTH AMERICA UNITED STATES IRELAND UNITED KINGDOM EUROPE MASSACHUSETTS INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH FDA CLINICAL TRIALS SOURCE: Iksuda Therapeutics Copyright Business Wire 2025. PUB: 06/30/2025 08:00 PM/DISC: 06/30/2025 08:00 PM

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store